Wang Zhenqian, Jiang Xiao, Zhang Long, Chen Han
Department of General Surgery 905th Hospital of the Chinese People's Liberation Army Navy Shanghai P.R. China.
Food Sci Nutr. 2023 May 26;11(8):4756-4772. doi: 10.1002/fsn3.3455. eCollection 2023 Aug.
Hepatocellular carcinoma is the fourth cause of death due to cancer and includes 90% of liver tumors. Therefore, in this study, it was tried to show that L. flower extract (ALOF) can protect hepatocytes against -diethylnitrosamine (DEN)-induced hepatocellular carcinoma. Totally, 70 Wistar rats were divided into seven groups ( = 10/group) of sham, DEN, treatment with silymarin (SIL; DEN + SIL), treatment with ALOF (DEN + 250 and 500 ALOF), and cotreatment with SIL and ALOF (DEN + SIL + 250 and 500 ALOF). At the end of the study, the serum levels of liver indices (albumin, total protein, bilirubin, C-reactive protein, ALT, AST, and ALP), inflammatory cytokines (IL-6, IL-1β, IL-10, and TNF-α), and oxidants parameters (glutathione peroxidase [GPx], superoxide dismutase [SOD], catalase [CAT] activity along with nitric oxide [NO] levels) were evaluated. The level of Bax, Bcl-2, Caspase-3, p53, PI3K, mTOR, and AKT genes were measured. ALOF in cotreatment with SIL was able to regulate liver biochemical parameters, improve serum antioxidant indices, and decrease the level of proinflammatory cytokines significantly ( < .05). ALOF extract in both doses of 250 and 500 mg/kg in cotreatment with SIL caused a significant ( < .05) decrease in the p53-positive cells and a significant ( < .05) increase in Bcl-2-positive cells. Therefore, ALOF was able to modulate the proliferation of cancer cells and protect normal cells through the regulation of Bax/Bcl-2/p53 and PI3K/Akt/mTOR signaling pathways. It seems that ALOF can be used as a prodrug or complementary treatment in the protection of hepatocytes in induced damages caused by carcinogens.
肝细胞癌是癌症致死的第四大原因,占肝脏肿瘤的90%。因此,在本研究中,试图证明L. flower提取物(ALOF)可以保护肝细胞免受二乙基亚硝胺(DEN)诱导的肝细胞癌。总共70只Wistar大鼠被分为七组(每组n = 10):假手术组、DEN组、水飞蓟宾治疗组(SIL;DEN + SIL)、ALOF治疗组(DEN + 250和500 ALOF)以及SIL与ALOF联合治疗组(DEN + SIL + 250和500 ALOF)。在研究结束时,评估了肝脏指标(白蛋白、总蛋白、胆红素、C反应蛋白、谷丙转氨酶、谷草转氨酶和碱性磷酸酶)、炎性细胞因子(白细胞介素-6、白细胞介素-1β、白细胞介素-10和肿瘤坏死因子-α)以及氧化参数(谷胱甘肽过氧化物酶[GPx]、超氧化物歧化酶[SOD]、过氧化氢酶[CAT]活性以及一氧化氮[NO]水平)的血清水平。检测了Bax、Bcl-2、Caspase-3、p53、PI3K、mTOR和AKT基因的水平。ALOF与SIL联合治疗能够调节肝脏生化参数,改善血清抗氧化指标,并显著降低促炎细胞因子水平(P < 0.05)。与SIL联合治疗的250和500 mg/kg剂量的ALOF提取物均导致p53阳性细胞显著减少(P < 0.05),Bcl-2阳性细胞显著增加(P < 0.05)。因此,ALOF能够通过调节Bax/Bcl-2/p53和PI3K/Akt/mTOR信号通路来调节癌细胞的增殖并保护正常细胞。似乎ALOF可以用作前体药物或辅助治疗,以保护肝细胞免受致癌物诱导的损伤。